Author:
Cardona-Acosta Astrid M.,Sial Omar K.,Parise Lyonna F.,Gnecco Tamara,Enriquez Marti Giselle,Bolaños-Guzmán Carlos A.
Abstract
AbstractIncreased use of benzodiazepines in adolescents have been reported, with alprazolam (ALP) being the most abused. Drug abuse during adolescence can induce changes with lasting consequences. This study investigated the neurobiological consequences of ALP exposure during adolescence in C57BL/6J male mice. Mice received ALP (0, 0.5, 1.0 mg/kg) once/daily (postnatal day 35–49). Changes in responsiveness to morphine (2.5, 5.0 mg/kg), using the conditioned place preference paradigm, were assessed 24-h and 1-month after ALP exposure. In a separate experiment, mice received ALP (0, 0.5 mg/kg) and then sacrificed 24-h or 1-month after treatment to assess levels of extracellular signal regulated kinase 1/2 (ERK1/2) gene expression, protein phosphorylation, and downstream targets (CREB, AKT) within the ventral tegmental area (VTA) and nucleus accumbens (NAc). ALP-pretreated mice developed a strong preference to the compartment(s) paired with a subthreshold dose (2.5 mg/kg) of MOR short-term, and this effect was also present in the 1-month group. Adolescent ALP exposure resulted in dysregulation of ERK-signaling within the VTA-NAc pathway 24-h and 1-month after ALP exposure. Results indicate ALP exposure during adolescence potentiates the rewarding properties of MOR and induces persistent changes in ERK-signaling within the VTA-NAc pathway, a brain circuit highly implicated in the regulation of both drug reward and mood- related behaviors.
Funder
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
College of Liberal Arts at Texas A&M University
Publisher
Springer Science and Business Media LLC
Reference92 articles.
1. Henderson, A., Wright, M. & Pond, S. M. Experience with 732 acute overdose patients admitted to an intensive care unit over six years. Med. J. Aust. 158, 28–30. https://doi.org/10.5694/j.1326-5377.1993.tb121644.x (1993).
2. Jones, C. M., Mack, K. A. & Paulozzi, L. J. Pharmaceutical overdose deaths, United States, 2010. JAMA 309, 657–659. https://doi.org/10.1001/jama.2013.272 (2013).
3. Gladden, R. M., O’Donnell, J., Mattson, C. L. & Seth, P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine—25 states, July-December 2017 to January-June 2018. MMWR Morb. Mortal. Wkly. Rep. 68, 737–744. https://doi.org/10.15585/mmwr.mm6834a2 (2019).
4. U.S. Food and Drug Administration. FDA requiring boxed warning updated to improved safe use of benzodiazepine drug class (2020). https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class.
5. PATS, 2013 Key Findings: Released July 23, 2014. https://drugfree.org/wp-content/uploads/2014/07/PATS-2013-KEY-FINDINGS1.pdf.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献